Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (228)

« Back to Publications

PD-1 blockade enhances functional vaccine-induced HIV-1 CD8+ T-cell responses in PWH receiving early ART

Marin M. et al, (2026), eBioMedicine, 123, 106070 - 106070

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

Chanda C. et al, (2025), The Lancet. Microbe, 6

Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.

Borthwick N. et al, (2025), The Lancet. Microbe, 6

Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine

Bruton J. and Hanke T., (2025), Vaccines, 13, 72 - 72

In danger: HIV vaccine research and development in Europe.

Tatoud R. et al, (2025), PLOS global public health, 5

PD-1 blockade enhances HIV-1 vaccine-induced CD8⁺ T-cell responses in PWH early ART-treated

Marin M. et al, (2024)

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Del Moral-Sánchez I. et al, (2024), NPJ vaccines, 9

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions

Kopycinski J. et al, (2023), Scientific Reports, 13

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Bailón L. et al, (2022), Nature medicine, 28, 2611 - 2621

Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination

Woods E. et al, (2021), npj Vaccines, 6

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines

Wee EG. et al, (2021), Molecular Therapy - Methods & Clinical Development, 21, 741 - 753

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

Fidler S. et al, (2020), The Lancet, 395, 888 - 898

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

Rosás-Umbert M. et al, (2020), Frontiers in immunology, 11

Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.

Mothe B. et al, (2020), EClinicalMedicine, 18

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Mothe B. et al, (2020), Frontiers in immunology, 11

Load More

1
2
3
4
5
6
7
...
»